TNF and inflammatory bowel disease: Vedolizumab (VDZ), which is a gut-selective antibody to α4β7 integrin for IBD treatment, has a favorable safety profile with low incidence rates of serious infections, infusion-related reactions, and malignancies.[9] However, its safety for patients with anti-TNF-alpha agent-associated active TB infection remains unclear.